Budesonide in the first line treatment of patients with autoimmune hepatitis

Olivas, Ignasi; Cobreros, Marina; Londoño, María-Carlota; Díaz-González, Álvaro.
Gastroenterol. hepatol. (Ed. impr.) ; 45(7): 561-570, Ago - Sep 2022. tab
Artículo en Inglés | IBECS (España) | ID: ibc-206918

Documentos relacionados

  1. Budesonide in the first line treatment of patients with autoimmune hepatitis.
  2. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration.
  3. Autoimmune hepatitis: Current and future therapies.
  4. Treatment of autoimmune hepatitis: Budesonide does not solve our problems.
  5. Overlooked Symptoms in Autoimmune Hepatitis Negatively Impact Many Facets of Life.
  6. [Guidelines on the diagnosis and management of autoimmune hepatitis (2021)].
  7. [Guidelines on the diagnosis and management of autoimmune hepatitis (2021)].
  8. Advances in the evaluation and treatment of autoimmune hepatitis.
  9. Profiling of mouse and human liver diseases identifies targets for therapeutic treatment of autoimmune hepatitis.
  10. Autoimmune Hepatitis-Challenging Diagnosis.